The principles of therapeutic strategies for AD formulated in the preceding section are supported by two naturally occurring mutations that modulate physiological cleavages within iAβ (or the Aβ segment of AβPP and C99) and either cause or protect from Alzheimer’s disease. The gene discussed is APP; the disease is early-onset autosomal dominant Alzheimer disease.